Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript
Arrowhead Pharmaceuticals, Inc. ( ARWR ) TD Cowen Treatment Advancements in Obesity and Related Disorders Summit November 24, 2025 1:30 PM EST Company Participants James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Everyone, and thank you for joining us at TD Cowen's 2025 Treatment Advances in Obesity Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. ( ARWR ) Q4 2025 Earnings Call November 25, 2025 4:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President Bruce Given - Chief Medical Scientist Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise James Hamilton - Chief Medical Officer and Head of R&D Daniel Apel - Chief Financial Officer Conference Call Participants Luca Issi - RBC Capital Markets, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Dina Ramadane - BofA Securities, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Michael Ulz - Morgan Stanley, Research Division Madison Wynne El-Saadi - B.
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript
Arrowhead Pharmaceuticals, Inc. ( ARWR ) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome November 18, 2025 1:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Bruce Given - Chief Medical Scientist Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce Given Conference Call Participants Ryan Mcelroy - Leerink Partners LLC, Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Farzin Haque - Jefferies LLC, Research Division Luca Issi - RBC Capital Markets, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Avraham Novick - Morgan Stanley, Research Division Chi Meng Fong - BofA Securities, Research Division John Peyton Bohnsack - TD Cowen, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division William Pickering - Sanford C.
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead
A busy period is ahead for Arrowhead Pharmaceuticals on regulatory, legal, and clinical fronts. The PDUFA date with the FDA for plozasiran is tomorrow, and an approval should be expected, but competitor Ionis is suing for infringement of its '333 patent. Ionis' olezarsen recently generated very strong phase 3 results in severe hypertriglyceridemia patients and these results offer positive read-through for plozasiran's phase 3 trial with data in mid-2026.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:10 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Welcome, everyone.
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place
Arrowhead stock is a Strong Buy due to significant pipeline progress, especially the upcoming FDA PDUFA review date of plozasiran for familial chylomicronemia syndrome. The PALISADE phase 3 trial for plozasiran showed robust efficacy in reducing triglycerides and acute pancreatitis risk, leading to an FDA PDUFA review date of November 18, 2025. Ongoing late-stage studies for severe hypertriglyceridemia (SHTG) and a lucrative Novartis partnership for ARO-SNCA further strengthen company's long-term growth prospects.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q3 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce D. Given - Corporate Participant Chief Medical Scientist - Corporate Participant Christopher R.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations for Arrowhead Christopher Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - Outgoing CFO Daniel Apel - Incoming CFO Conference Call Participants Maury Raycroft - Jefferies Jason Gerberry - Bank of America Jasmine Fels - UBS Patrick Trucchio - H.C. Wainwright & Company Luca Issi - RBC Edward Tenthoff - Piper Sandler Mike Ulz - Morgan Stanley Mayank Mamtani - B.
Arrowhead Pharmaceuticals Is Finally Arriving
Arrowhead Pharmaceuticals, Inc. has streamlined its focus, now boasting 19 clinical programs, including 4 phase 3 trials and 4 phase 2 trials. Plozasiran shows superior results in triglyceride reduction and dosing frequency compared to its main competitor, Olezarsen, with a pivotal PDUFA date on November 18. ARWR's strong financial position is bolstered by a recent deal with Sarepta, extending its cash runway into 2028.
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital David Lebowitz - Citi Jasmine Fels - UBS Maury Raycroft - Jefferies Edward Tenthoff - PSC Patrick Trucchio - H.C. Wainwright Mayank Mamtani - B.
